Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




Nilotinib Shows Better Early Responses Than Imatinib in CML
Link ID 20972
Title Nilotinib Shows Better Early Responses Than Imatinib in CML
Url http://www.medscape.com/viewarticle/713786?src=rss
Description Nilotinib induced significantly higher and faster rates of major molecular response and complete cytogenetic response than imatinib when given as first-line therapy. Medscape Medical News
Category Articles > Hematology-Oncology
Keywords
Date Dec 15, 2009
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Hematology-Oncology
1. Fast Track for Cancer Drugs: Shut It Down or Speed It Up?
  FDA officials discuss the how the current system for accelerated approval is not working well; new changes being proposed include the idea of approval straight after phase 1. Medscape Medical News
Category:   Articles > Hematology-Oncology


2. New Standard of Care for Advanced Adrenocortical Carcinoma?New Standard of Care for Advanced Adrenoc
  Mitotane combined with etoposide, doxorubicin, and cisplatin is more effective than mitotane plus streptozocin for advanced adrenocortical carcinoma, according to the first trial comparing regimens. Medscape Medical News
Category:   Articles > Hematology-Oncology


3. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer: F1000 Ranking "Changes Clin
  The EGFR mutation is now testable on a large scale and treatable with gefitinib in patients with lung cancer. Faculty of 1000 Medicine
Category:   Articles > Hematology-Oncology


4. Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial
  The safety and efficacy of sorafenib is examined in patients 70-years and older with advanced renal cell carcinoma.
Journal of the National Cancer Institute
Category:   Articles > Hematology-Oncology


5. Additional Therapy for High-Risk Prostate Cancer Treated With Surgery: What Is the Evidence?
  This review article discusses the evidence for neoadjuvant and adjuvant treatment approaches when surgery is chosen as the definitive therapy for high-risk prostate cancer. Expert Review of Anticancer Therapy
Category:   Articles > Hematology-Oncology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS